Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.AEZ


Primary Symbol: T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Bullboard Posts
Post by TechTargeton Nov 05, 2015 9:55pm
91 Views
Post# 24264721

AEZ on radar

AEZ on radarInteresting volume patterns this one?  Just appeared on my radar.

Bashers are brainless!  Anyone who can't understand what splits and reserve-splits/rollback need some basic math courses. Sorry...  I know, t's hard to understand for some.

Let me try to explain:

You can have 100 little beads or one big ball. They are both the same mass and price, just that the bigger ball is easier to carry especially if you plan to carry many.   The 100 little beads are messy.  Yes, little kids prefer to play with them and trade  beads but they are of no interest to the big boys and everyone else.

Most importantly large exchanges such as the TSE and Nasdaq (both on which Zentaris trades on) require biggest balls because guys interested in those need them by the truckload.  Beads are just messy, get on the ground and feed the rats.

So this stock has NO CHOICE but to consolidate the shares (beads) into one ball. 

So assuming a SP of 10 cents (fair value) at 100/1, you are looking at a $10 stock.  Larger institutional buyers can then buy in.  No brainer!

There's no other option  guys! All legitimate holder should vote yes and I'm sure the vote will be yes because the stock becomes worthless otherwise.  So you pick!  $0 or $10, what do you prefer to see change at 5% or 10%.  It's all percentages anyway!

This stock is actually cheap from what I can see? They have over $25M in cash last quarter and have take significant steps to reduce cash burn and turn arond this stock.  The market cap is less than $50M from an al time high of $200+M

Can anyone provide an intelligent, critical review of the products and pipeline discussed in the latest investor relations slides?  Looks very impresive but I have many questions. Like: are peer-reviewed scientific analysis of the products?  Clinical trials, etc.  Is it just sales stuff of actually based on science?
Bullboard Posts